Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
March 5, 2007
- Mochida Joins Novartis to Promote Diovan
March 5, 2007
- NEW PRODUCT
February 26, 2007
- METI to Start Health Information Platform Initiative
February 26, 2007
- Kyowa Hakko Achieves Personnel Cost Cutting Target Ahead of Schedule
February 26, 2007
- JPA Working Out Clear Position Toward Promotion of GE Drugs
February 26, 2007
- Intage Surveying Doctors on MR Calls and Their Impact
February 26, 2007
- No Marked Rise in Share of Generics from Jun. to Oct. 2006
February 26, 2007
- BUSINESS NEWS IN BRIEF
February 26, 2007
- Toyama Prefecture Tests Generics from Makers Under Its Control
February 26, 2007
- SEMINAR
February 26, 2007
- TOPIC about Novo Nordisk Pharma
February 26, 2007
- Regulatory Systems in Japan Need Improvements in 5 Areas: Mr Dunoyer of EFPIA Japan
February 26, 2007
- Pfizer J-GAP Survey
February 26, 2007
- New Review, Consultation Fees Proposed
February 26, 2007
- DSP Is Seeing Synergistic Effects: President Miyatake
February 26, 2007
- Toxicogenomics Research Project
February 26, 2007
- CMIC to Go to the West to Promote Japan-Centered Clinical Trials
February 26, 2007
- R&D NEWS IN BRIEF
February 26, 2007
- Roche Diagnostics Aims for 7.1% Growth in Sales in Bearish Market
February 26, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…